Identification of therapeutic targets applicable to clinical strategies in ovarian cancer - Test2 - elhamkhani - TriplyDB

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

http://www.wikidata.org/entity/Q28829029

about

BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).

P2860

Q41612803-BAFBF3BC-0FBE-42A0-97C7-ABB71627410A

P2860

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

http://www.wikidata.org/entity/Q28829029

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

@ast

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

@en

type

label

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

@ast

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

@en

prefLabel

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

@ast

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

@en

P1433

Q28829029-26B1CD98-4E47-4347-AD32-FF1B0989F6EE

P1476

Q28829029-629F9543-2ECD-49E1-8AA5-BA679FF83C3E

P2093

Q28829029-3B36817D-919B-44AB-B5AC-F939F0D5BBB7

Q28829029-54055478-418A-46CE-86FF-0EFFBB72208D

Q28829029-76D943F3-7335-42DD-B8D2-38E9B475B3D2

Q28829029-9B63A3E9-3213-42D6-9F5F-692DB6700FDF

Q28829029-B63044E7-D62D-46F4-93DB-DD2DDA3FD2C9

Q28829029-C004BDD3-DA84-452F-A23A-F1871411554B

Q28829029-D3DAA61C-6C34-4DB3-9EBE-AB19043DACB4

P2860

Q28829029-174C6D30-0C89-4AD0-96D4-6F90FBE76E45

Q28829029-1C05899E-DFA6-4BF4-9477-5B2C8730F935

Q28829029-233E00F5-74C4-48EA-926A-BDAEE1138DD5

Q28829029-34D1BD6E-436E-4C6E-B4CD-C65174B8B151

Q28829029-351D181F-FEEE-407F-9930-173D500D8DD3

Q28829029-46C09480-EA0B-4716-A994-37BB4EAED743

Q28829029-48AEFC6E-44BE-4700-919F-950FD5F3A5D0

Q28829029-7D8B3C16-5571-499F-A96A-5832A1B912F7

Q28829029-8FD56480-0A60-4993-8FC5-32B99C1F03D8

Q28829029-994E115D-AE38-4793-86D6-F5C1091CE27A

P2888

Q28829029-A765EE3B-846A-47F8-A5F6-8A9A8CADE164

P304

Q28829029-8517F7F6-58CB-4171-BEFE-894C316909CE

P31

Q28829029-F3B905D0-D287-4D0E-9E2B-02250DBBA57A

P3181

Q28829029-7730C190-2687-4342-B379-80DC88A445AC

P356

Q28829029-ACA0FE14-146C-4060-A55A-66BC0C678024

P407

Q28829029-7C7ECEDA-345A-4B61-9FEA-32A171C18E80

P433

Q28829029-49E25AEE-1128-4E98-8472-B6F7BFD77657

P478

Q28829029-4864A800-DEE3-4EAF-A3A8-3E734A8DB58A

P50

Q28829029-36C54E6A-6CE5-4F68-AB13-42A6ED4E2BEA

P577

Q28829029-B8A6785F-541A-4AD5-9EA3-57FDDFE68922

P6179

Q28829029-235B4AFC-4F39-4028-8913-8F81CFA32D5D

P698

Q28829029-C9E8AA1A-4996-4CA6-B17B-922437EB3541

P932

Q28829029-13E2F65C-F955-43AE-AE36-7DD4FDCD5A76

P3181

P356

S12885-016-2675-5

P1433

P1476

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer

@en

P2093

Carrie House

http://www.w3.org/2001/XMLSchema#string

Elizabeth Jordan

http://www.w3.org/2001/XMLSchema#string

Georgios Pongas

http://www.w3.org/2001/XMLSchema#string

Lidia Hernandez

http://www.w3.org/2001/XMLSchema#string

Marianne K Kim

http://www.w3.org/2001/XMLSchema#string

Natasha Caplen

http://www.w3.org/2001/XMLSchema#string

Sirisha Chakka

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated genomic analyses of ovarian carcinoma

Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.

Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling.

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival

Emerging landscape of oncogenic signatures across human cancers.

Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21.

In vitro enrichment of ovarian cancer tumor-initiating cells

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.

P2888

s12885-016-2675-5

P304

678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3917328

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S12885-016-2675-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Christina M Annunziata

P577

2016-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023256035

http://www.w3.org/2001/XMLSchema#string

P698

27558154

http://www.w3.org/2001/XMLSchema#string

P932

4997769

http://www.w3.org/2001/XMLSchema#string